IFNA1 and systemic lupus erythematosus: It is reported that 50–75% of adult patients with SLE have elevated production of type I IFN, giving rise to an increased IFN signature (87), while patients with active SLE benefit from the treatment with anifrolumab, a human monoclonal antibody against type I IFN receptor subunit 1, blocking the activation of type I IFNs (88).